Immune cell attack on lupus: first human trial launches
Disease control
Not yet recruiting
This early-stage trial tests a new treatment called KN5501 for adults with moderate to severe lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) to target and destroy faulty B cells that drive the disease. The ma…
Phase: PHASE1 • Sponsor: Ruitherapeutics Co., LTD • Aim: Disease control
Last updated May 15, 2026 11:54 UTC